Sei Investments Co. boosted its position in Omnicell, Inc. (NASDAQ:OMCL) by 36.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,652 shares of the company’s stock after acquiring an additional 1,242 shares during the quarter. Sei Investments Co.’s holdings in Omnicell were worth $200,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of OMCL. BlackRock Inc. raised its holdings in Omnicell by 139,475.2% in the first quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after acquiring an additional 4,484,128 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Omnicell by 99.6% in the first quarter. Wells Fargo & Company MN now owns 561,295 shares of the company’s stock valued at $22,817,000 after acquiring an additional 280,017 shares in the last quarter. Tributary Capital Management LLC acquired a new stake in Omnicell in the first quarter valued at approximately $8,908,000. Westfield Capital Management Co. LP raised its holdings in Omnicell by 29.7% in the first quarter. Westfield Capital Management Co. LP now owns 925,244 shares of the company’s stock valued at $37,611,000 after acquiring an additional 211,698 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Omnicell by 324.4% in the first quarter. Russell Investments Group Ltd. now owns 204,440 shares of the company’s stock valued at $8,311,000 after acquiring an additional 156,264 shares in the last quarter. 96.35% of the stock is currently owned by hedge funds and other institutional investors.
OMCL has been the topic of several analyst reports. ValuEngine raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, May 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $47.00 target price (up previously from $43.00) on shares of Omnicell in a report on Tuesday, June 13th. Benchmark Co. raised their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. Finally, BidaskClub raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $51.57.
In other Omnicell news, Chairman Randall A. Lipps sold 31,527 shares of the stock in a transaction on Monday, June 19th. The stock was sold at an average price of $42.87, for a total value of $1,351,562.49. Following the sale, the chairman now directly owns 196,551 shares of the company’s stock, valued at $8,426,141.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Randall A. Lipps sold 40,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at $9,780,377.76. The disclosure for this sale can be found here. Insiders sold 202,309 shares of company stock worth $9,787,437 over the last ninety days. 3.77% of the stock is owned by corporate insiders.
Shares of Omnicell, Inc. (NASDAQ OMCL) opened at 50.00 on Monday. The firm’s market cap is $1.87 billion. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $52.70. The firm’s 50-day moving average is $49.10 and its 200-day moving average is $42.99.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.38 EPS. Equities analysts expect that Omnicell, Inc. will post $1.30 earnings per share for the current fiscal year.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.